Dr. Tripathy Discusses Immunotherapy in HER2+ Breast Cancer

Debu Tripathy, MD
Published: Monday, Jun 19, 2017



Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.

With many mature data being presented in the near future, Tripathy says that trials with combinations of standard chemotherapy and immunotherapy, trastuzumab (Herceptin) and pertuzumab (Perjeta), are promising.

On the other hand, Tripathy adds, estrogen receptor-positive/HER2-negative breast cancers have been shown to be less immunogenic.
 
SELECTED
LANGUAGE


Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.

With many mature data being presented in the near future, Tripathy says that trials with combinations of standard chemotherapy and immunotherapy, trastuzumab (Herceptin) and pertuzumab (Perjeta), are promising.

On the other hand, Tripathy adds, estrogen receptor-positive/HER2-negative breast cancers have been shown to be less immunogenic.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x